Literature DB >> 17301214

A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Kevin Fabrizio1, Abraham Groner, Marianne Boes, Liise-anne Pirofski.   

Abstract

Antibody-based approaches to pneumococcal disease may hold promise for immunocompromised patients in whom vaccines are less immunogenic and/or in the context of antimicrobial resistance. Antibody-mediated protection against experimental pneumococcal pneumonia has been shown to depend on immunoregulation, but the relationship between antibody and protection against pneumococcal sepsis and immunoregulation has not been examined. Similarly, the requirement for B and T cells for antibody efficacy is not known. In this study, we determined the efficacy of the human pneumococcal capsular polysaccharide serotype 3-specific antibody, A7 (immunoglobulin M [IgM]), in secretory IgM (sIgM)(-/-), CD4(-/-), CD8(-/-), muMT(-/-), and SCID mice and investigated its effect on cytokine and chemokine expression in sera and spleens from mice with intact cellular immunity. A7 is known to be protective against systemic infection with serotype 3 and to require complement for efficacy. Compared to that of an isotype control antibody, A7 administration prolonged the survival of mice of each immunodeficient strain and was associated with a significant reduction in CFU in blood, lung, and spleen samples and a significantly reduced level of keratinocyte-derived chemokine (KC), interleukin-6 (IL-6), and macrophage inflammatory protein-2 (MIP-2) expression in normal and sIgM(-/-) mice. Studies with mice treated with penicillin revealed similar reductions in CFU and similar levels of IL-6, KC, or MIP-2 expression in A7- and penicillin-treated mice. These findings demonstrate that natural IgM and B and T cells are dispensable for A7-mediated protection against experimental pneumococcal sepsis and suggest that the efficacy of antibody-mediated protection depends on immunomodulation. Taken together, our data extend the association between antibody-mediated protection and immunomodulation to protection against systemic pneumococcal infection and to a clinically important serotype often responsible for pneumococcal sepsis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301214      PMCID: PMC1865609          DOI: 10.1128/CVI.00374-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  54 in total

Review 1.  New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae.

Authors:  A Tomasz
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

2.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA.

Authors:  R AUSTRIAN; J GOLD
Journal:  Ann Intern Med       Date:  1964-05       Impact factor: 25.391

3.  CD4-T-lymphocyte interactions with pneumolysin and pneumococci suggest a crucial protective role in the host response to pneumococcal infection.

Authors:  Aras Kadioglu; William Coward; M Joseph Colston; Colin R A Hewitt; Peter W Andrew
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

4.  Combined schedule of 7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal vaccine in children and young adults with sickle cell disease.

Authors:  L Vernacchio; E J Neufeld; K MacDonald; S Kurth; S Murakami; C Hohne; M King; D Molrine
Journal:  J Pediatr       Date:  1998-08       Impact factor: 4.406

5.  The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice.

Authors:  Jeremy S Brown; Tracy Hussell; Sarah M Gilliland; David W Holden; James C Paton; Michael R Ehrenstein; Mark J Walport; Marina Botto
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-11       Impact factor: 11.205

6.  Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children.

Authors:  G S Giebink; J E Foker; Y Kim; G Schiffman
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

7.  Antibody mediated suppression of secondary IgM response in nude mice against vesicular stomatitis virus.

Authors:  S Charan; R M Zinkernagel
Journal:  J Immunol       Date:  1986-04-15       Impact factor: 5.422

8.  Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.

Authors:  Lisa J Moore; Alison C Pridmore; Steven K Dower; Robert C Read
Journal:  J Infect Dis       Date:  2003-09-17       Impact factor: 5.226

9.  B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

Authors:  Michael S Diamond; Bimmi Shrestha; Anantha Marri; Darby Mahan; Michael Engle
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 10.  Immunomodulators as an antimicrobial tool.

Authors:  Liise-anne Pirofski; Arturo Casadevall
Journal:  Curr Opin Microbiol       Date:  2006-08-22       Impact factor: 7.934

View more
  21 in total

Review 1.  The importance of natural IgM: scavenger, protector and regulator.

Authors:  Michael R Ehrenstein; Clare A Notley
Journal:  Nat Rev Immunol       Date:  2010-10-15       Impact factor: 53.106

2.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

3.  Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.

Authors:  Jay A Fishman; David N Iklé; Robert A Wilkinson
Journal:  Transpl Int       Date:  2017-05-02       Impact factor: 3.782

4.  High-dose immunoglobulin preparations improve survival in a CLP-induced rat model of sepsis.

Authors:  Takahisa Yoshikawa; Hiroya Takeuchi; Koichi Suda; Taku Miyasho; Shingo Yamada; Minoru Okamoto; Yoshio Kawamura; Ikuro Maruyama; Masaki Kitajima; Yuko Kitagawa
Journal:  Langenbecks Arch Surg       Date:  2011-11-25       Impact factor: 3.445

5.  The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response.

Authors:  Beza Seyoum; Masahide Yano; Liise-anne Pirofski
Journal:  Vaccine       Date:  2011-08-22       Impact factor: 3.641

6.  The Other Side of the Coin: Anti-inflammatory Antibody Therapy for Infectious Diseases.

Authors:  David L Goldman
Journal:  Infect Immun       Date:  2020-01-22       Impact factor: 3.441

7.  A serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibody requires Fcγ receptor III and macrophages to mediate protection against pneumococcal pneumonia in mice.

Authors:  Sarah Weber; Haijun Tian; Nico van Rooijen; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

8.  A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice.

Authors:  Christopher R Doyle; Jee-Young Moon; Johanna P Daily; Tao Wang; Liise-Anne Pirofski
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

Review 9.  IgM in microbial infections: taken for granted?

Authors:  Rachael Racine; Gary M Winslow
Journal:  Immunol Lett       Date:  2009-06-17       Impact factor: 3.685

10.  High-dose intravenous immunoglobulin G improves systemic inflammation in a rat model of CLP-induced sepsis.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Akira Hasegawa; Nobuhiko Asai; Takayuki Noguchi
Journal:  Intensive Care Med       Date:  2008-05-24       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.